We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

94 hedge funds and large institutions have $78.9M invested in iShares US Pharmaceuticals ETF in 2020 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

24,167% more call options, than puts

Call options by funds: $728K | Put options by funds: $3K

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

3% more funds holding

Funds holding: 91 → 94 (+3)

4.72% less ownership

Funds ownership: 72.49% → 67.77% (-4.7%)

6% less capital invested

Capital invested by funds: $83.7M → $78.9M (-$4.8M)

21% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 28

Holders
94
Holders Change
+3
Holders Change %
+3.3%
% of All Funds
1.9%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
22
Reduced
28
Closed
10
Calls
$728K
Puts
$3K
Net Calls
+$725K
Net Calls Change
-$304K

Top Buyers

Rank Fund Capital Flow
1
CFGS
Concourse Financial Group Securities
Alabama
+$3.63M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.08M
3
Bank of America
Bank of America
North Carolina
+$565K
4
Wells Fargo
Wells Fargo
California
+$499K
5
FTUS
Flow Traders U.S.
New York
+$387K

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$5.15M
2
Citadel Advisors
Citadel Advisors
Florida
-$5.13M
3
Stifel Financial
Stifel Financial
Missouri
-$1.15M
4
SRSA
S.R. Schill & Associates
Washington
-$990K
5
TRCT
Tower Research Capital (TRC)
New York
-$953K
Name Holding Trade Value Shares
Change 		Change in
Stake
CPSC
51
Carl P. Sherr & Co
Massachusetts
$201K +$199K +3,681 New
Citigroup
52
Citigroup
New York
$155K – – –
Franklin Resources
53
Franklin Resources
California
$125K – – –
US Bancorp
54
US Bancorp
Minnesota
$118K -$8.09K -150 -7%
FDCDDQ
55
Federation des caisses Desjardins du Quebec
Quebec, Canada
$111K – – –
BAM
56
Belpointe Asset Management
Nevada
$100K +$98.5K +1,827 New
MAWCM
57
Mine & Arao Wealth Creation & Management
California
$92K +$35.9K +666 +66%
AWA
58
Arkadios Wealth Advisors
Georgia
$79.4K +$162 +3 +0.2%
SFS
59
Sowell Financial Services
Arkansas
$78K -$3.88K -72 -5%
PNC Financial Services Group
60
PNC Financial Services Group
Pennsylvania
$75K +$13.8K +255 +23%
FCH
61
Freestone Capital Holdings
Washington
$74.1K +$73.3K +1,359 New
BFC
62
Bedel Financial Consulting
Indiana
$70K – – –
VFA
63
Valeo Financial Advisors
Indiana
$68K – – –
Northwestern Mutual Wealth Management
64
Northwestern Mutual Wealth Management
Wisconsin
$64K +$485 +9 +0.8%
AA
65
Advisory Alpha
Michigan
$61K +$58.7K +1,089 New
CAAS
66
Capital Asset Advisory Services
Michigan
$60K – – –
GWM
67
Geneos Wealth Management
Colorado
$59K – – –
AP
68
Advisors Preferred
Maryland
$45K +$44.2K +819 New
IA
69
IFP Advisors
Florida
$43K – – –
AAMA
70
Advanced Asset Management Advisors
Ohio
$42K – – –
JHCP
71
Jackson Hole Capital Partners
Oklahoma
$41K – – –
LWM
72
Liberty Wealth Management
California
$40K +$162 +3 +0.4%
ICM
73
Islay Capital Management
Texas
$34K – – –
GRP
74
Global Retirement Partners
California
$34K +$162 +3 +0.5%
ASN
75
Advisory Services Network
Georgia
$31K +$30.4K +564 New
1 2
3
4 5

IHE Hedge Fund Activity: Q3 2020 in Review

94 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2020, worth a combined $78.9M — down 5.7% from $83.7M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IHE positions and 10 closed out — a net gain of 4 holders — while 22 added to existing stakes and 28 trimmed.

The largest buyer was Concourse Financial Group Securities, adding an estimated $3.63M. The largest seller was Royal Bank of Canada, cutting an estimated $5.15M.

  • 94 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2020, up from 91 in Q2 2020.
  • Funds reported $78.9M of iShares US Pharmaceuticals ETF stock for Q3 2020, down 5.7% quarter-over-quarter.
  • 14 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2020 and 10 closed out, a net change of +4 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2020 was Concourse Financial Group Securities, an estimated $3.63M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2020 was Royal Bank of Canada, an estimated $5.15M sold.

Based on aggregated 13F filings for Q3 2020.